The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by Canaccord Genuity on November 6, 2024. The analyst firm set a price target for $32.00 expecting VERV to rise to within 12 months (a possible 561.16% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by Canaccord Genuity, and Verve Therapeutics maintained their buy rating.

The last upgrade for Verve Therapeutics Inc happened on August 25, 2022 when Stifel raised their price target to $56. Stifel previously had a hold for Verve Therapeutics Inc.

There is no last downgrade for Verve Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a maintained with a price target of $29.00 to $32.00. The current price Verve Therapeutics (VERV) is trading at is $4.84, which is out of the analyst’s predicted range.